Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair

  • Benedikt Koell
  • Mathias Orban
  • Jessica Weimann
  • Mohammad Kassar
  • Nicole Karam
  • Michael Neuss
  • Aniela Petrescu
  • Christos Iliadis
  • Matthias Unterhuber
  • Marianna Adamo
  • Cristina Giannini
  • Bruno Melica
  • Sebastian Ludwig
  • Steffen Massberg
  • Fabien Praz
  • Roman Pfister
  • Holger Thiele
  • Ralph Stephan von Bardeleben
  • Stephan Baldus
  • Christian Butter
  • Philipp Lurz
  • Stephan Windecker
  • Marco Metra
  • Anna Sonia Petronio
  • Jörg Hausleiter
  • Edith Lubos
  • Daniel Kalbacher
  • EuroSMR Investigators

Related Research units

Abstract

BACKGROUND: Although mitral valve transcatheter edge-to-edge repair (M-TEER) achieves symptomatic benefit for a broad spectrum of patients with relevant secondary mitral regurgitation, conflicting data exist on its prognostic impact.

OBJECTIVES: Adapted enrollment criteria approaching those used in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and MITRA-FR (Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation) trials were retrospectively applied to a European real-world registry to evaluate the influence of the respective criteria on outcomes.

METHODS: A total of 1,022 patients included in the EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry and treated with M-TEER (November 2008 to September 2019) were stratified into COAPT-eligible (n = 353 [34.5%]) and COAPT-ineligible (n = 669 [65.5%]) as well as MITRA-FR-eligible (n = 408 [48.3%]) and MITRA-FR-ineligible (n = 437 [51.7%]) groups.

RESULTS: Although the stratification of patients according to adapted MITRA-FR criteria led to comparable outcomes regarding all-cause mortality (P = 0.19), the application of adapted COAPT enrollment criteria demonstrated lower mortality rates in COAPT-eligible compared with COAPT-ineligible patients (P < 0.001). Multivariable Cox regression analysis identified New York Heart Association functional class IV (hazard ratio [HR]: 2.29; 95% confidence interval [CI]: 1.53-3.42; P < 0.001), logarithmic N-terminal pro-brain natriuretic peptide (HR: 1.47; 95% CI: 1.24-1.75; P < 0.001), and right ventricular-to-pulmonary arterial coupling (HR: 0.10; 95% CI: 0.02-0.57; P = 0.009) as independent predictors of outcome. Yet improvement of functional outcome was demonstrated in a subset of patients irrespective of COAPT eligibility status.

CONCLUSIONS: In this real-world cohort of patients with secondary mitral regurgitation undergoing M-TEER, the retrospective application of adapted COAPT enrollment criteria successfully identified a specific phenotype demonstrating lower mortality rates. On the contrary, stratification according to adapted MITRA-FR criteria resulted in comparable outcomes.

Bibliographical data

Original languageEnglish
ISSN0735-1097
DOIs
Publication statusPublished - 14.12.2021
PubMed 34886961